VeriSIM Life and Mayo Clinic Team Up to Co-develop New Therapies
VeriSIM Life and Mayo Clinic are collaborating to develop new promising drug candidates.
VeriSIM Life (VeriSIM), a US-based artificial intelligence (AI)-enabled company that provides drug discovery and drug development services, has entered into a collaboration with Mayo Clinic to improve the preclinical translation of promising drug candidates for development.
Under the agreement, VeriSIM will use its proprietary BIOiSIM platform and Translational Index technology to reduce the number of outsourced preclinical experiments. These platforms are also expected to help de-risk R&D decisions early on to ensure expedited development of novel, safe, and highly efficacious drugs, according to a June 28, 2022 company press release. Mayo Clinic physician researchers will work with VeriSIM in key disease areas, including oncology, hematology, bone/joint-disorders, and neurological diseases.
“This collaboration will explore the full potential of our combined approach to developing best-in-class drug candidates to serve patients’ unmet needs,” said Jo Varshney, founder and CEO of VeriSIM Life, in the press release.
Source: VeriSIM Life
Psilera, Hesperos Agree to Accelerate Organ-on-a-Chip Treatment for Frontotemporal Dementia
June 9th 2025The partnership leverages the Hesperos organ-on-a-chip platform in the preclinical development of Psilera’s lead compound targeting the progressive neurological disorder for which treatment options are few.
